ADAMTS13, RECOMBINANT-KRHN: 68 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
68
Total FAERS Reports
1 (1.5%)
Deaths Reported
20
Hospitalizations
68
As Primary/Secondary Suspect
1
Life-Threatening
First Report: 20221201 · Latest Report: 20250712
What Are the Most Common ADAMTS13, RECOMBINANT-KRHN Side Effects?
#1 Most Reported
Pregnancy
9 reports (13.2%)
#2 Most Reported
No adverse event
7 reports (10.3%)
#3 Most Reported
Thrombotic thrombocytopenic purpura
6 reports (8.8%)
All ADAMTS13, RECOMBINANT-KRHN Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Pregnancy | 9 | 13.2% | 0 | 2 |
| No adverse event | 7 | 10.3% | 0 | 0 |
| Thrombotic thrombocytopenic purpura | 6 | 8.8% | 0 | 1 |
| Abortion spontaneous | 5 | 7.4% | 0 | 0 |
| Headache | 5 | 7.4% | 0 | 0 |
| Incorrect dose administered | 5 | 7.4% | 0 | 1 |
Who Reports ADAMTS13, RECOMBINANT-KRHN Side Effects? Age & Gender Data
Gender: 60.7% female, 39.3% male. Average age: 27.6 years. Most reports from: US. View detailed demographics →
Is ADAMTS13, RECOMBINANT-KRHN Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2022 | 1 | 0 | 1 |
| 2024 | 13 | 0 | 5 |
| 2025 | 8 | 0 | 5 |
What Is ADAMTS13, RECOMBINANT-KRHN Used For?
| Indication | Reports |
|---|---|
| Thrombotic thrombocytopenic purpura | 32 |
| Product used for unknown indication | 17 |
| Congenital thrombotic thrombocytopenic purpura | 13 |
| Prophylaxis | 7 |
Official FDA Label for ADAMTS13, RECOMBINANT-KRHN
Official prescribing information from the FDA-approved drug label.